Business Context and Reporting Period
This Form 6-K filing by InterCure Ltd. covers the month of June 2026, specifically dated June 15, 2026. The report serves to disseminate a press release regarding two major corporate developments: the initiation of a strategic review of U.S. medical cannabis opportunities following historic federal rescheduling, and the completion of the initial closing of the Botanico acquisition.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document is a procedural filing to distribute a press release and does not contain a financial statement or quantitative performance data.
Material Changes
- Strategic Review: InterCure has initiated a strategic review of U.S. medical cannabis opportunities, driven by historic federal rescheduling of cannabis.
- Acquisition Milestone: The company completed the initial closing of its acquisition of Botanico.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the strategic review and the Botanico acquisition closing. The filing does not provide specific financial guidance, detailed risk factors, or contingencies beyond the context of the federal rescheduling event and the acquisition activity.
Investor Verification Checklist
- Verify the specific terms and financial impact of the Botanico acquisition initial closing.
- Review the full press release (Exhibit 99.1) for details on the scope and timeline of the U.S. medical cannabis strategic review.
- Confirm the implications of the "historic federal rescheduling" on InterCure's regulatory environment and market access.